Valrubicin
- PMID: 40127366
- Bookshelf ID: NBK612974
Valrubicin
Excerpt
Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially anthracyclines such as valrubicin.[1] It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence. The manufacturer recommends that breastfeeding be discontinued during valrubicin therapy and for 2 weeks after the final dose.
Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[2] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.
References
-
- Pistilli B, Bellettini G, Giovannetti E, et al. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: How should we counsel cancer patients about breastfeeding? Cancer Treat Rev 2013;39:207-11. - PubMed
Publication types
LinkOut - more resources
Full Text Sources